
PRESS RELEASE

Seeing Machines Technical Paper Series on Non-Fatigue Impairment launched

Alcohol-related driver impairment remains a key factor in road accidents globally as current roadside strategies don't go far enough

Canberra, 17 December 2025: Seeing Machines Limited, a global leader in vision-based monitoring technology, has released *Part One of its new Technical Paper series*, dedicated to advancing the understanding and detection of non-fatigue driver impairment, starting with intoxication. This initiative marks a major step in the company's broader focus on leveraging its Driver Monitoring System (DMS) technology to address critical safety challenges on roads, globally.

Alcohol continues to be a leading cause of road trauma worldwide, contributing significantly to fatalities and injuries despite ongoing roadside based preventative efforts. Recognising these persistent risks, Seeing Machines has launched its capability to harness the power of DMS technology to identify impairment from alcohol in real time.

The Company's latest research highlights the limitations of relying solely on Blood Alcohol Concentration (BAC) as a benchmark for impairment. Traditional approaches often overlook the way impairment unfolds over time, resulting in gaps between BAC progression and real-world driver performance. Seeing Machines' DMS technology aims to bridge this divide by directly assessing functional impairment in real time, ensuring enhanced detection sensitivity and more effective in-cabin intervention strategies.

"Roadside alcohol testing has delivered great reductions in road injury over many years. Our goal is to complement these existing roadside programs by leading the introduction of in-vehicle approaches," said Dr Mike Lenné, Chief Safety Officer at Seeing Machines. "By incorporating the temporal dynamics of impairment, how it evolves during both the ascending and descending phases of intoxication from alcohol as well as the complex effects of other drugs such as cannabis, our technology can reflect real-time real-world risks and provide greater safety protections to road users."

To support this approach, Seeing Machines is working with leading experts and universities, conducting pioneering experiments that explore the disconnect between BAC readings and actual driver impairment. These collaborations underscore the Company's commitment to developing solutions that align technological innovation with real-world safety outcomes.

Part One of the Technical Paper series is now available, with future instalments set to explore additional aspects of non-fatigue impairment, including from cannabis, and further enhance the capabilities of DMS technology for road safety.

Click here for Part One: <https://seeingmachines.com/technical-paper-series-intoxication>

-ends-

About Seeing Machines (LSE: SEE)

Seeing Machines is a global company founded in 2000 and headquartered in Australia, is an industry leader in vision-based monitoring technology that enable machines to see, understand and assist people. Seeing Machines is revolutionising global transport safety. Its technology portfolio of AI algorithms, embedded processing and optics, power products that need to deliver reliable real-time understanding of vehicle operators. The technology spans the critical measurement of where a driver is looking, through to classification of their cognitive state as it applies to accident risk. Reliable "driver state" measurement is the end-goal of Driver Monitoring Systems (DMS) technology. Seeing Machines develops DMS technology to drive safety for Automotive, Commercial Fleet, Off-road and Aviation. The company has offices in Australia, USA, Europe and Asia, and supplies technology solutions and services to industry leaders in each market vertical. www.seeingmachines.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAEDLBFELLZFBK